fah hospital policy blog

Perspectives on health policy affecting America’s hospitals and the patients we serve.

Category Archives: pharmaceuticals

FAH Comments on International Pricing Index Model ANPRM

December 21, 2018 | FAH Policy Blog Team

Category: Pharmaceuticals

Today, the FAH commented on the Administration’s International Pricing Index Model for Medicare Part B Drugs Advance Notice of Proposed Rulemaking (ANPRM). The ANPRM signaled the Administration’s interest in testing an Innovation Center model which would dramatically change the manner in which Part B drugs are priced, acquired and paid for in the Medicare program.

Read More »

Groups Urge Congress to Protect Seniors from Rising Drug Prices

November 13, 2018 | FAH Policy Blog Team

Category: Medicare, Pharmaceuticals

The Federation of American Hospitals joined 16 other groups in sending a letter to Congressional leaders today urging them to preserve the actions taken in the Bipartisan Budget Act (BBA) of 2018 to protect seniors and taxpayers from out-of-control drug prices during the upcoming lame duck session of Congress.

Read More »

FAH Leader Comments on the Trump Administration’s Proposal To Change Medicare Drug Prices

October 25, 2018 | Chip Kahn

Category: Financing, Medicare, Pharmaceuticals

We agree with the President that it is time to reduce the drug tab for Americans, but actions need to be focused on the real culprit - manufacturers’ prices - not the frontline hospitals and physicians who administer and prescribe those medicines. We look forward to examining the details and fine print of the Administration’s proposals.

Read More »

FAH Comments on 2019 OPPS Proposed Rule

September 24, 2018 | FAH Policy Blog Team

Category: Financing, Pharmaceuticals, Quality

This afternoon FAH filed comments with CMS regarding the 2019 Hospital Outpatient Prospective Payment System (OPPS) proposed rule.

Read More »